Pfizer Inc ( (PFE) ) has released its Q4 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Pfizer Inc., a leading global pharmaceutical company, is known for developing and distributing biopharmaceutical products, including vaccines and medicines, with a strong focus on research and development in the healthcare sector.
In its latest earnings announcement, Pfizer reported robust financial results for the full-year 2024, with revenues reaching $63.6 billion, reflecting a 7% operational growth compared to the previous year. The company also reaffirmed its financial guidance for 2025, indicating stability and continued strategic focus.
Among the key financial highlights, Pfizer’s non-COVID product revenue saw a significant rise of 12% operationally for the full year. The fourth quarter alone witnessed a 21% operational revenue growth, excluding contributions from Paxlovid and Comirnaty. The company also achieved major cost savings of $4 billion and set a new target of $4.5 billion by the end of 2025, alongside advancing its R&D pipeline.
Pfizer continues to focus on strengthening its product portfolio, with notable growth from products like Vyndaqel, Eliquis, and Xtandi. Despite challenges such as declining Comirnaty revenues, the company remains on a solid trajectory, evidenced by its strategic cost realignment and robust financial performance.
Looking ahead, Pfizer’s management remains optimistic about enhancing shareholder value by improving R&D productivity and maintaining strong financial health, as reflected in their 2025 guidance of revenues between $61.0 and $64.0 billion and adjusted EPS in the range of $2.80 to $3.00.
